Utilizing a Multidisciplinary Team Approach to Bladder Cancer Treatment
Oncology pharmacists are important to the oncology care team, as they can bring a unique perspective to treatment planning, according to Kirollos S. Hanna, PharmD, BCPS, BCOP, FACC.
AEs to Monitor With Enfortumab Vedotin/Pembrolizumab in Advanced Bladder Cancer
Neuropathy is an adverse effect that can occur when enfortumab veodtin is administered to patients with locally advanced or metastatic urothelial carcinoma.
Navigating Cisplatin Shortages and the Need for Legislation
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Reducing Dosage May Help to Conserve Cisplatin in Various Populations
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
Cisplatin Imports From China Are Aiding in Alleviating U.S. Chemo Shortage
While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.
Pharmacy Expert Highlights Impact of Chemo Shortage on Bladder Cancer Space
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses what strategies are being used to treat patients with bladder cancer during the chemotherapy shortage.
Non-BCMA Targeting Bispecifics in MM and Future Directions in Care
Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
Emerging BCMA Targeting Bispecifics in Multiple Myeloma
Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.
Supportive Care Strategies for Patients with MM on Bispecifics Treatment
Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.
Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM
Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.
Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting
Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.
Long-Term Monitoring for CRS and AEs With Bispecific Therapy
Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.
Initial Monitoring for CRS and AEs in Patients With MM on Bispecifics
Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.
Multiple Myeloma: Addressing Financial Barriers to Bispecifics
Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.
Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma
Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.
Administering Step-up and Treatment Doses of Bispecifics in Patients With MM
Frances A. Bell, NP, leads a conversation on key steps taken leading up to the initial administering of bispecific therapy in patients with multiple myeloma.
Where Do Bispecifics Fit in the Multiple Myeloma Treatment Paradigm?
Shared insight on the role bispecifics will play in multiple myeloma management as other novel agents and clinical trials continue to enter the landscape.
Erdafitinib’s Road to Approval and Use in Urothelial Carcinoma
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, offers a perspective on a clinical quandary published recently in the journal ONCOLOGY.
Treatment Considerations With Bispecifics in Multiple Myeloma
Panelists provide a broad-view perspective on established treatment pathways with bispecifics in multiple myeloma and the most prevalent challenges tied to this class of therapy.
Multiple Myeloma: Overview of an Evolving Treatment Landscape
Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.